QD202 Study for Recent Stroke Treated With Clot-Busting Medicine
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether a new drug called QD202 can help protect the brain and improve recovery when given alongside standard clot-busting therapy (thrombolysis) for acute ischemic stroke. You would be in the trial if you had a stroke in the last 24 hours and are receiving or planning to receive thrombolytic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stroke (blood clot blocking brain blood flow) within the last 24 hours
- You are between 18 and 85 years old
- You are receiving or plan to receive thrombolytic therapy (clot-busting medicine injected into the vein)
- Before this stroke, you were independent or nearly independent in daily activities (modified Rankin Scale score of 0 or 1)
- Your stroke severity falls in a moderate range (NIHSS score 6–20) with some arm or leg weakness
- You are not allergic to any component of the study drug or placebo
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial tests an investigational drug called B2065 for people who have had a recent ischemic stroke (a stroke caused by a blockage in a blood vessel in the brain). The goal is to see if it is safe and if it might help improve recovery when given within 36 hours of stroke symptoms starting.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.